Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Clin Colorectal Cancer. 2014 Jun 26;13(3):192–198. doi: 10.1016/j.clcc.2014.05.003

Figure 1.

Figure 1

Incidence of grade 3 or higher hematologic and non-hematologic adverse events among older mCRC patients receiving anti EGFR agents alone or in combination with chemotherapy.

(*) Statistically significant difference between the incidence of adverse events seen among patients treated with monotherapy versus combination therapy.